Zacks.com featured highlights TD SYNNEX, Ameriprise, Harmony and Newell Brands

For Immediate Release

Chicago, IL – August 7, 2026 – Stocks in this week’s article TD SYNNEX CORP SNX, Ameriprise Financial AMP, Harmony Biosciences HRMY and Newell Brands NWL

4 Stocks Trading Near 52-Week Highs with More Upside Potential

Investors generally consider a stock's 52-week high a good criterion for an entry or exit point. Stocks touching new 52-week highs are often predisposed to profit-taking, resulting in pullbacks and trend reversals. 

Moreover, given the high price, investors often wonder if the stock is overpriced. While the speculation is not completely baseless, not all stocks hitting a 52-week high are necessarily overpriced.

Investors might lose out on top gainers in an attempt to avoid the steep prices.

Stocks such as TD SYNNEX CORP, Ameriprise Financial, Harmony Biosciences and Newell Brands are expected to maintain their momentum and keep scaling new highs. More information on a stock is necessary to determine whether there is scope for further upside.

Here, we discuss a strategy to find the right stocks. The technique borrows from the basics of momentum investing and bets on “buy high, sell higher.”

52-Week High: A Good Indicator

Many times, stocks that hit a 52-week high fail to scale higher despite having potential. This is because investors fear that the stocks are overvalued and expect the price to crash.

Overvaluation is natural for most of these stocks as investors’ focus (or willingness to pay the premium) has helped them reach this level. But that does not always indicate an impending decline. Factors such as robust sales, surging profit levels, earnings growth prospects and strategic acquisitions, which encouraged investors to bet on these stocks, could keep them motivated if there are no tangible negatives. In other words, the momentum might continue.

Also, when a string of positive developments dominates the market, investors find their underreaction unwarranted, even if there are no company-specific driving forces.

Here are our four picks out of the 21 stocks that made it through the screen:

TD SYNNEX Corp is poised for near-term upside, supported by strong strategic fundamentals across both its business units. Hyve Solutions continues to capitalize on robust hyperscaler AI infrastructure demand, while the Distribution segment maintains broad-based momentum across cybersecurity, cloud, and AI. In June 2026, management issued third-quarter guidance for non-GAAP gross billings of $27.2–$28.2 billion and non-GAAP EPS of $4.25–$4.75. A 9% year-over-year quarterly dividend increase to $0.48 per share further signals durable cash generation capacity. 

In July 2026, TD SYNNEX was named a Fortinet global distributor, unlocking multi-region engagement opportunities across Europe and Asia. August 2026 saw new AI cloud storage and communications partnerships across Asia-Pacific, expanding its international distribution footprint and reinforcing revenue visibility going forward.

The stock has returned 52.8% in the past six months. It has a trailing four-quarter earnings surprise of 21.7%, on average.

Ameriprise Financial heads into the second half of 2026 with strong fundamental tailwinds. Advisor productivity hit a record $1.2 million per advisor, up 12%. Wrap assets of $732 billion, up 19%, reflect deepening client engagement. Firm-wide AUM/A/A advanced to a record $1.8 trillion, up 14%. The Huntington National Bank partnership, bringing 260 advisors and nearly $28 billion in assets, is set to more than offset Comerica-related outflows by the fourth quarter. Ameriprise's July 2026 announcement of $1 billion in technology and AI spend is generating measurable advisor efficiency gains. In June, the firm earned the BISA Technology Innovation Award for its Signature Wealth Program. The declared $1.70 quarterly dividend, backed by the guidance to return 85–90% of operating earnings to shareholders, underscores capital strength.
    
The stock has returned 4.1% in the past six-month period. It delivered a trailing four-quarter earnings surprise of 5.56%, on average. 

Harmony Biosciences entered the second-half of 2026 on a solid fundamental footing. The company reiterated full-year WAKIX net revenue guidance of $1.0–$1.04 billion, supported by a growing patient base of 8,950 in the second quarter and disciplined commercial execution. The FDA's July 2026 acceptance of the Pitolisant GR NDA, targeting a PDUFA date of April 1, 2027, adds a near-term regulatory catalyst. 

The August 2026 Phase 1 SAD data for orexin-2 agonist BP-205 demonstrated a ~25-hour half-life, rapid onset, and clean tolerability, with Phase 1b initiating in the third quarter of 2026 and Phase 2 studies planned for mid-2027. Six narcolepsy and idiopathic hypersomnia abstracts at SLEEP 2026 in June bolstered franchise credibility. A $962.5 million cash position supports a self-funded pipeline while WAKIX exclusivity holds through 2030.

This stock has surged 3.2% in the past six-month period. It has a trailing four-quarter negative earnings surprise of 13.97%, on average. 

Newell Brands is building a compelling near-term fundamental case. Full-year 2026 guidance has been raised across all key metrics, with net sales expected to grow 1%–2%, normalized operating margin at 10.0%–10.4%, and normalized EPS of 73 cents–77 cents. Operating cash flow guidance has been raised to approximately $400 million. A €40 million planned investment in French operations — spanning automation, AI-driven digitization, and sustainability — signals durable global capability-building. 

Brand momentum is accelerating. Coleman's multi-year partnership with Kane Brown and Sharpie's collaboration with Under Armour open new consumer audiences. A new $800 million revolving credit facility extended to 2031 strengthens liquidity. Third-quarter 2026 guidance of 2%–3% net and core sales growth, with gross productivity savings, points to further near-term margin improvement.

This stock has gained 35.9% in the past six months. It has a trailing four-quarter earnings surprise of 39.98%, on average. 

Why Haven't You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2970072/4-stocks-trading-near-52-week-high-with-more-upside-potential

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.

Follow us on Twitter:  https://www.twitter.com/zacksresearch

Join us on Facebook:  https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: [email protected]

Visit: https://www.zacks.com/

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research